San Diego Business Journal

Accumetrics Product Gaining Foothold in Canada

By Julie Gallant Friday, August 10, 2012

Two deals under way are making Sorrento Valley-based Accumetrics Inc.’s VerifyNow System more widely available in Canada.

VerifyNow, a system for measuring platelet reactivity to multiple antiplatelet agents, has been licensed for clinical use by Health Canada, making it available to hospitals and clinical laboratories in Canada.

Additionally, Accumetrics has signed an agreement with Canadian firm Force 3 Medical Inc. for the distribution of the VerifyNow System to hospitals, health centers, cardiologists and other cardiovascular professionals in Canada. With the addition of Force 3 Medical to Accumetrics’ distribution partners, Accumetrics has local representation in more than 70 countries worldwide.

Antiplatelet medication such as aspirin, Plavix and its generic clopidogrel are typically prescribed to cardiovascular disease patients to prevent heart attacks, stroke and other potentially life-threatening cardiovascular events. Patients who do not respond adequately to their antiplatelet therapies may be at greater risk of these adverse events. The VerifyNow System is a platform and suite of tests for the assessment of platelet reactivity to major antiplatelet therapies.

Dianah Schmidt, executive director for market development and clinical education for Accumetrics, said doctors can use VerifyNow to make more informed decisions that can lead to more cost effective and clinically appropriate actions.

“What physicians do is use the VerifyNow test to see if patients’ blood is basically responding adequately to the medications they’ve been provided,” Schmidt said. “Data studies have shown patients who aren’t responding adequately have a significantly greater rate of events such as heart attack, stroke or death.”

Schmidt said Canada is a potentially lucrative market because Canadians want to be efficient with their resources in the health care system and they have a keen interest in moving beyond research and into actual patient application.